Education
About Us
Working with TipRanks
Follow Us
Lantheus (LNTH)
NASDAQ:LNTH
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
1.64Last Year’s EPS
1.69Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: 24.22%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
Lantheus reported strong revenue growth driven by Pylarify and DEFINITY, alongside strategic acquisitions expected to bolster future growth. However, challenges include increased operating expenses and a net loss for the quarter. Despite these challenges, the company remains optimistic about its pipeline and strategic direction.Company Guidance
During the Lantheus Fourth Quarter and Full Year 2024 Conference Call, the company provided guidance for 2025, anticipating a full-year net revenue in the range of $1.54 billion to $1.61 billion, reflecting growth of 1% to 5% over 2024. Pylarify, a leading PSMA PET imaging agent, is expected to achieve low to mid-single-digit growth, while DEFINITY is projected to grow at a similar rate despite facing headwinds. The company forecasts a gross profit margin similar to 2024's 68% and anticipates fully diluted adjusted earnings per share between $7.00 and $7.20, an increase of 3.5% to 6.5%. Lantheus plans to generate $550 million to $600 million in free cash flow and highlight the potential for sustained double-digit revenue growth starting in 2026, driven by strategic transactions and pipeline expansions.Record-Breaking Revenue and Growth
Lantheus achieved $1.534 billion in revenue for the full year 2024, an increase of 18.3%, with Pylarify sales surpassing $1 billion, establishing it as the first-ever radio diagnostic blockbuster.
Strategic Acquisitions
Lantheus announced acquisitions of Life Molecular Imaging and Evergreen Theragnostics, expected to enhance radiopharmaceutical capabilities and drive sustained double-digit revenue growth beginning in 2026.
Strong Performance of DEFINITY
DEFINITY, the leading ultrasound enhancing agent, achieved fourth quarter net sales of $86.2 million, up 17.9% year-over-year.
CMS Policy Favorable for Radiopharmaceuticals
The new CMS payment policy provides separate payment for innovative radiopharmaceutical diagnostics, benefiting products like Pylarify.
Future Pipeline Potential
Lantheus is excited about its pipeline, including MK-6240 and NAV-4694 for Alzheimer's diagnostics, and expects to file NDAs in 2025 and 2026.
---
LNTH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LNTH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $80.05 | $93.25 | +16.49% |
| Nov 06, 2024 | $114.96 | $91.17 | -20.69% |
| Jul 31, 2024 | $109.77 | $104.83 | -4.50% |
| May 02, 2024 | $67.39 | $78.18 | +16.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Lantheus (LNTH) report earnings?
Lantheus (LNTH) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Lantheus (LNTH) earnings time?
Lantheus (LNTH) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LNTH EPS forecast?
LNTH EPS forecast for the fiscal quarter 2025 (Q1) is 1.64.
---
